Early detection of placental inflammation by MRI enabling protection by clinically relevant IL-1Ra administration
Early detection of placental inflammation by MRI enabling protection by clinically relevant IL-1Ra administration
复制标题
DOI：
10.1016/j.ajog.2012.01.008
复制
发表时间：
2012-04-01
影响因子：
9.8
通讯作者：
Sebire, Guillaume
中科院分区：
文献类型：
--
作者：
Girard, Sylvie;Tremblay, Luc;Sebire, Guillaume
目的：我们研究了磁共振成像（MRI）是否可以用于检测不可逆的组织损伤之前检测胎盘炎症。接下来，我们测试是否这种早期检测将使管理的治疗（即，白细胞介素-1受体拮抗剂[IL-1 Ra]）在一个现实的临床时间后diagnosis.Study Design：孕鼠腹腔注射脂多糖与/不延迟IL-1 Ra。在注射后不同时间进行MRI检查，并收集胎盘进行比较。胎盘炎症通过测定炎性细胞因子的水平进行评估。结果：胎盘炎症通过MRI检测到早在3小时后母体管理的脂多糖，伴随着IL-1 β上调。这是在任何组织损伤之前观察到的，其仅在给予脂多糖后24小时出现。延迟IL-1 Ra管理（MRI诊断后）保护胎盘，所看到的保存组织的完整性和有限的巨噬细胞浸润在胎盘parenchyma.CONCLUSION：这些研究结果建立了一个非侵入性的诊断方法，在子宫内检测胎盘炎症，将允许管理胎盘保护性干预在临床相关的延迟诊断后。
OBJECTIVE: We studied whether magnetic resonance imaging (MRI) could be used to detect placental inflammation before the detection of irreversible tissue damage. Next, we tested whether this early detection would enable the administration of treatment (ie, interleukin-1 receptor antagonist [IL-1Ra]) in a realistic clinical time after diagnosis.STUDY DESIGN: Pregnant rats were injected intraperitoneally with lipopolysaccharide with/without delayed IL-1Ra. MRI was performed at different time after the injection, and placentas were collected for comparison. Placental inflammation was assessed by determination of the levels of inflammatory cytokines.RESULTS: Placental inflammation was detected by MRI as early as 3 hours after maternal administration of lipopolysaccharide, concom-itantly to IL-1 beta up-regulation. This was observed before any tissue damage, which appeared only at 24 hours after the administration of lipopolysaccharide. Delayed IL-1Ra administration (after MRI diagnosis) protected the placenta, as seen by the preserved tissue integrity and limited macrophages infiltration in the placental parenchyma.CONCLUSION: These findings established a noninvasive diagnostic method for early in utero detection of placental inflammation that would allow the administration of placentoprotective intervention within a clinically relevant delay after diagnosis.